TY - JOUR
T1 - Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice
AU - Dvorakova, Katerina
AU - Dorr, Robert T.
AU - Gallegos, Alfred
AU - McClure, Thomas
AU - Powis, Garth
N1 - Funding Information:
Supported by grants CA17094 and ES 06694.
PY - 1997/8/29
Y1 - 1997/8/29
N2 - Oryzalin [3,5-dinitro-N,N-di(n-propyl)benzensulfanilamide] is a widely used sulfonamide herbicide that selectively inhibits microtubule formation in algae and higher plants. Oryzalin has also been found to be an inhibitor of intracellular free Ca2+ signalling in mammalian cells and to have antitumor activity in animals. Despite its widespread use there have been no reports of the pharmacokinetics of oryzalin in animals or man. A reversed-phase high-performance liquid chromatographic (HPLC) method was developed to measure oryzalin in biological fluids. Following repeated daily administration of oryzalin to mice by the i.p. route at 200 mg/kg, or the p.o. route at 300 mg/kg, peak plasma concentrations of up to 25 μg/ml were achieved. The half life for oryzalin in plasma of mice given i.p. oryzalin was 14.3 h with a clearance of 0.07 l/h. A major metabolite of oryzalin, N-depropyloryzalin, was identified in plasma and its structure confirmed by mass spectral analysis (M+H+=305). This metabolite was cleared more rapidly than oryzalin with a half life of 1.15 h and a clearance of 0.17 l/h. N-Depropyloryzalin caused similar inhibition of colony formation by HT-29 colon cancer cells as oryzalin with IC50=8 μg/ml. The results suggest that oryzalin and its N-depropyl metabolite can inhibit tumor colony formation at pharmacologically achievable levels.
AB - Oryzalin [3,5-dinitro-N,N-di(n-propyl)benzensulfanilamide] is a widely used sulfonamide herbicide that selectively inhibits microtubule formation in algae and higher plants. Oryzalin has also been found to be an inhibitor of intracellular free Ca2+ signalling in mammalian cells and to have antitumor activity in animals. Despite its widespread use there have been no reports of the pharmacokinetics of oryzalin in animals or man. A reversed-phase high-performance liquid chromatographic (HPLC) method was developed to measure oryzalin in biological fluids. Following repeated daily administration of oryzalin to mice by the i.p. route at 200 mg/kg, or the p.o. route at 300 mg/kg, peak plasma concentrations of up to 25 μg/ml were achieved. The half life for oryzalin in plasma of mice given i.p. oryzalin was 14.3 h with a clearance of 0.07 l/h. A major metabolite of oryzalin, N-depropyloryzalin, was identified in plasma and its structure confirmed by mass spectral analysis (M+H+=305). This metabolite was cleared more rapidly than oryzalin with a half life of 1.15 h and a clearance of 0.17 l/h. N-Depropyloryzalin caused similar inhibition of colony formation by HT-29 colon cancer cells as oryzalin with IC50=8 μg/ml. The results suggest that oryzalin and its N-depropyl metabolite can inhibit tumor colony formation at pharmacologically achievable levels.
KW - Oryzalin
UR - http://www.scopus.com/inward/record.url?scp=0030886942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030886942&partnerID=8YFLogxK
U2 - 10.1016/S0378-4347(97)00261-2
DO - 10.1016/S0378-4347(97)00261-2
M3 - Article
C2 - 9323548
AN - SCOPUS:0030886942
SN - 1572-6495
VL - 696
SP - 275
EP - 281
JO - Journal of Chromatography B: Biomedical Applications
JF - Journal of Chromatography B: Biomedical Applications
IS - 2
ER -